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Neoplastic cell content determination is crucial for biomarker testing. It is known that interobserver
variation exists, but largescale data are missing about variation in tumor delineation and cell content
determination. Results were obtained from the external quality assessment program for metastatic
colorectal cancer from the European Society of Pathology (NZ 5776 observations). The study included
three parts: current practices were surveyed, neoplastic cell content estimations and delineations were
retrieved from stained slides, and clinical reports were analyzed. Seventeen of 43 pathologists determined
the neoplastic cell content in a tumor-rich area for DNA extraction and took immune cells (nZ 37), tumor
cell distribution (nZ 33), desmoplastic stroma (nZ 30), necrosis (nZ 29), and mucus (nZ 23) into
account. The selected area was highly variable, and the average difference between the highest and lowest
estimation ranged between 51% and 78% (2011 to 2017). The number of overestimations was alarmingly
high in samples containing <30% tumor cells. Of concern is that 33 of 105 laboratories reported a wild-
type result in a sample without tumor in 2017. Standardization of neoplastic cell content determination
is needed for test outcome interpretation. The authors’ data show variation in estimation practices, tumor
delineations and estimations, and interpretation problems (n Z 226 reports). Further training
for selecting the most suitable block and creating clear reports is urgently needed. (J Mol Diagn 2018, 20:
455e464; https://doi.org/10.1016/j.jmoldx.2018.03.003)
Precision medicine, an established concept in the daily care
of patients with cancer, has caused an increase in the
number of biomarkers that need to be tested in the ﬁeld of
molecular pathology.1 For example, RAS testing before
antieepidermal growth factor receptor therapy is mandatory
for patients with metastatic colorectal cancer.2 The reli-
ability and accuracy of biomarker testing is essential for
optimal patient care, and errors might lead to the denial of
treatment to a patient who could have beneﬁted from it or to
the overuse of these expensive therapeutic agents, which can
even cause major adverse events.3
The selection of themost optimal cell block, selection of the
area for DNA extraction, and neoplastic cell content deter-
mination are critical steps in the molecular testing process to
avoid false-negative results. Many laboratories have been
using a nonenext-generation sequencing (NGS)-based com-
mercial molecular method,4 which requires a minimal amount
of tumor DNA as validated by the kit manufacturer. This
minimum amount of tumor DNA varies per testing method
and can be translated to a minimum number of neoplastic
cells.5 In addition, laboratories that use a laboratory-developed
kit need to validate their method and determine a minimal
required number of neoplastic cells. Accurate estimation is
especially important for testing with NGS, because tumor
cellularity is essential to distinguish between signals and
noise.6 Moreover, an accurate neoplastic cell content estima-
tion helps to set a minimal read depth, because samples with
low cellularities require higher coverages.7,8
There is no gold standard to determine the percentage of
neoplastic cells.9 Pathologists are often trained to estimate
the neoplastic cell content by looking at a hematoxylin and
eosin (H&E)estained formalin-ﬁxed, parafﬁn-embedded
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tissue slide. Previous studies already indicated that this
estimation by pathologists is prone to interobserver
variation.10e13 This variation is especially critical for sam-
ples with a low number of neoplastic cells, because over-
estimations might lead to false-negative results.14e16
It is uncertain which estimation strategies for the neoplastic
cell content are used in Europe and how the area in the tissue
to be used forDNAextraction is indicated. Although previous
studies have identiﬁed variation in the estimations, no
largescale data are available about the selection of the tumor
zone in a sample or the estimations.8e11 Therefore, this study
aimed to gain insight in the current practices in Europe and to
identify factors that impact the way the tumor is delineated
and the neoplastic cell content estimated.
Materials and Methods
Study Context
Insight in current practices of estimating the neoplastic cell
content was gained based on data from the external quality
assessment (EQA) program for metastatic colorectal cancer
between 2011 and 2017. This is an annual program organized
by the European Society of Pathology (ESP) Quality Assur-
ance Foundation (Brussels, Belgium). Participating labora-
tories in the EQA scheme received 30 pretested, blank,
formalin-ﬁxed, parafﬁn-embedded tissue slides originating
from 10 different samples for analysis with their routine pro-
tocols. After analysis, laboratories were asked to submit the
following: genotyping results, a questionnaire about their
laboratory characteristics and testing strategy, diagnostic re-
ports for three cases based on mock clinical information, and
scans of the H&E-stained slides on which the area selected for
DNA extraction was delineated and the neoplastic cell content
was estimated. Two independent assessors (J.H.v.K. and
G.D.H.), who are experts in molecular pathology of metastatic
colorectal cancer, assessed the results.
Study Design
This study consisted of three parts. In the ﬁrst part, the methods
for determining the neoplastic cell content were retrieved from
the questionnaires that were part of the ESP Colon EQA
schemes between 2011 and 2017, and these data were
supplemented by an additional questionnairewithmore speciﬁc
questions regarding the individual who estimated the cellu-
larity, the estimation protocol, integration with micro- and/or
macrodissection, andpost-analytical use in 2017 (Supplemental
Appendix S1). The second part of the study covered variation in
cellularity estimations and how the zone for DNA extraction
was delineated; therefore, general questionnaires of the ESP
Colon EQA schemes and images scanned by the laboratory of
H&E slides on which the area for DNA extraction was delin-
eated from 2011 to 2017 were used. In the third part, infor-
mation regarding ways of reporting the neoplastic cell content
was retrieved from the questionnaire of the ESP Colon EQA
schemes of 2016 and 2017, and uploaded pathology reports.
Questionnaires were designed using FormDesk software
version 4.0.14 (Innovero Software Solutions B.V., Wassenaar,
the Netherlands) and provided to the participants via their
private account on the website (EQA, http://kras.eqascheme.
org, last accessed January 27, 2018). Nonrespondents
received e-mail reminders 14 and 30 days after the initial
invitation.
Data Analysis
Table 1gives anoverviewof thenumber of samples thatwas sent
between 2011 and 2017, the number of participants that gave
their estimations, and the number of scheme organizers. Due to
the large number of participants, different scheme organizers
distributed samples during the schemes of 2011 to 2016.4,17
Variation in neoplastic cell estimations was calculated in
two ways: based on the average estimation for each sample
and based on a consensus value. Consensus was reached after
independent determination by two pathologists with more
than 10 years of experience in molecular pathology. In addi-
tion, laboratories uploaded scans of the H&E-stained slide on
which the area for DNA extraction was delineated.
Delineations were categorized in six categories (Figure 1).
Small circles and small squares were chosen when the
diagonal diameter of the area was smaller than 5 mm. Precise
tumor shape was chosen when the zone was indicated with
dots. For statistical analysis, delineations were also bundled
into gross methods (gross tumor shape, gross square, gross
circle), precise methods (precise tumor shape, small circle,
small square), and whole tumor section. Error rates were
calculated as the ratio of the number of participants that made a
Table 1 Overview of the ESP Colon EQA Scheme Data Set
ESP colon EQA
scheme year
Number of scheme
organizers
Number of participants
who submitted a questionnaire
Number of participants
who submitted H&E slides
2011 10 124 125
2012 10 105 101
2013 8 131 123
2014e2015 9 125 118
2016 8 123 116
2017 1 105 97
EQA, external quality assessment; ESP, European Society of Pathology; H&E, hematoxylin and eosin.
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genotyping or technical error and the total number of partici-
pants. Genotyping errors consisted of reporting a false-
positive or false-negative result or a wrong mutation, and
examples of technical errors were problems with DNA
extraction, library preparation, probe hybridization, and so on.
Statistical Methodology
Statistical analysis was performed with c2 tests for comparison
of categorical variables, paired t-tests for continuous variables,
and one-way analysis of variance followed by Tukey honest
signiﬁcant difference analysis for a mixture of continuous and
categorical variables. P  0.05 was considered signiﬁcant.
Bonferroni corrections were applied when necessary. All
statistical analyses were performed using R Software version
3.4.0 (The R Foundation for Statistical Computing, Vienna,
Austria).
Results
Variability in Estimation Processes of Neoplastic Cell
Content Exists
In the ﬁrst part of the study, the methods for determining the
neoplastic cell content were analyzed. Figure 2A shows
which individuals were involved in the determination of the
neoplastic cell content in daily practice. In the majority of
laboratories, this was the pathologist, but in some labora-
tories, technicians or molecular biologists were doing the
primary determination with subsequent conﬁrmation by a
pathologist. It was also of interest whether one group per-
formed better than the others. No signiﬁcant differences in
error rates for genotyping (P > 0.05; 95% CI, 0.20 to
0.15) were observed between determination by the pathol-
ogist alone and determination by the molecular biologist or
technician followed by conﬁrmation by the pathologist.
There were only three participating laboratories where
technicians or molecular biologists performed the estimation
without conﬁrmation by a pathologist. For improving reader
friendliness of this article, the pathologist refers to the
individual who estimates the neoplastic cell content.
Survey results of 43 of 102 laboratories (42%) gave more
detailed information on how the content of neoplastic cells
was determined in daily practice in 2017 (Figure 2B). The
largest group of pathologists (40%) determined the
neoplastic cell content as the ratio of neoplastic cells to all
cells in a tumor-rich area selected for DNA extraction. Only
9% used their speciﬁc protocol for the determination (eg,
detailed description of the magniﬁcations used for deﬁning
the area with most viable neoplastic cells and the estima-
tion). Manually counting cells in a limited number of areas
was done in three laboratories.
There was variation, not only in the methods for esti-
mating the neoplastic cell content, but also in the way tumor
zones were delineated (Table 2). Pathologists who estimated
the neoplastic cell content in a selected area also indicated
which factors were taken into account for annotating that
area. Factors that were considered important were inﬁltra-
tion by immune cells (n Z 37; 86%), spread of neoplastic
cells (n Z 33; 77%), desmoplastic stroma (n Z 30; 70%),
necrosis (n Z 29; 67%), mucus (n Z 23; 53%), and fat
(nZ 2; 5%). Spread of neoplastic cells means the presence
of clusters of a few neoplastic cells spread over the tissue
slide.
To deﬁne the current state of the art, this study also
covered tumor enrichment methodologies used in 2017.
Three laboratories (7%) did not perform any form of
dissection, and these three laboratories made no error during
the ESP Colon Scheme of 2017. These laboratories used
three different testing methods: a noneNGS-based com-
mercial kit (KRAS/BRAF Mutation Analysis Panel Kit;
EntroGen, Woodland Hills, CA), an NGS-based commercial
kit (TruSight Tumor 15; Illumina, San Diego, CA), and a
noneNGS-based laboratory-developed technique (LDT;
dideoxy sequencing). The other laboratories performed
macrodissection (n Z 32; 74%), microdissection (n Z 2;
5%), or both (nZ 6; 14%). There were as many laboratories
taking tissue directly from the tissue block as from the tissue
slide. When tissue was taken from a slide, most laboratories
(58%) used dry scraping. Others used wet scraping (32%) or
laser-guided microdissection (11%).
Figure 1 Categorization of delineation methods of tumor area. A: Gross
circle. B: Gross square. C: Gross tumor shape. D: Small circle (diagonal area
diameter <5 mm). E: Small square (diagonal area diameter <5 mm). F:
Precise tumor shape (zone indicated with dots).
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Several Factors Inﬂuence Variation in Neoplastic Cell
Content and Delineation of the Tumor Zone
Results on the extent of the variation of neoplastic cell
content estimations between pathologists showed that the
differences between the highest and the lowest estimations
were between 52% and 78% (Figure 3). The average devi-
ation from the sample mean and consensus lay between 12%
and 23%. More underestimations (estimation of at least 20%
lower than the average value) than overestimations (esti-
mation of at least 20% greater than the average value) were
made (Table 3). For samples with a consensus value around
the diagnostic threshold of most testing methods (30% of
neoplastic cells),5 the percentage of overestimations was
58%, on average (Figure 4).
It was also studiedwhich factorsmight inﬂuence neoplastic
cell content estimations and how pathologists delineate the
tumor-rich zone (Table 4). No correlation was seen between
the neoplastic cell content estimation and the slide rank,
which is an indicator for the place in the blockwhere the tissue
slide was taken. Pathologists who used precise delineation
methods (small circle, small square, or precise tumor shape)
made higher estimations than pathologists who use gross
delineation methods (gross circle, gross square, gross tumor
shape, and whole tumor section). Laboratory accreditation
did not have an impact on the estimation, but inﬂuenced the
way the tumor zone is delineated, because pathologists in
nonaccredited laboratories were using more gross delineation
methods (gross tumor shape, gross square, and gross circle)
and whole tumor sections. Estimations and delineations also
differed among European regions (Supplemental Table S1).
In the southern and southeastern parts of Europe, higher
estimations were made and more precise delineations of the
tumor zone were given (Figure 5). The use of noneNGS-
based LDTs was correlated with higher estimations as
compared with noneNGS-based commercial kits and NGS.
In addition, noneNGS-based LDT methods were related to
lower method sensitivities than noneNGS-based commercial
kits and NGS (P < 0.0001). Consequently, there was a
negative correlation between the sensitivity of the analysis
method and the neoplastic cell content estimation. Labora-
tories that used a method that required a high percentage of
neoplastic cells also used more precise ways to delineate the
tumor zone. For NGS, a further distinctionwasmade between
commercial and laboratory-developed NGS techniques. The
same principles as for noneNGS-based commercial kits and
noneNGS-based LDTs applied. In 2017, estimations from
laboratories that use laboratory-developed NGS techniques
were higher (P < 0.001) and delineations were more precise
(P < 0.0001) than laboratories that use commercial NGS
techniques. For the other years, statistical evidence could only
be obtained for the correlation between the delineation
method and the NGS technique, although the same trends
were observed for the relation with the estimations.
Making genotyping errors was correlated with higher
estimations, but not with the delineation method, except for
2013 and 2014 to 2015. In those years, genotyping errors
were correlated with using gross delineation methods and/or
Figure 2 A: Distribution of individuals involved in the determination of
the neoplastic cell content (ESP colon schemes of 2011 to 2017). B: Dis-
tribution of the methods for the determination of the neoplastic cell
content.
Table 2 Methods That Were Used for the Indication of the Tumor Area
Delineation
method per slide
2011
(N Z 954)
2012
(N Z 799)
2013
(N Z 984)
2014e2015
(N Z 1178)
2016
(N Z 1153)
2017
(N Z 873)
Gross tumor shape 44% 21% 27% 30% 25% 33%
Gross square 6% 4% 4% 6% 6% 7%
Gross circle 8% 5% 4% 4% 6% 4%
Precise tumor shape 36% 56% 53% 43% 39% 32%
Small square* 0% 1% 5% 1% 0% 1%
Small circle* 0% 5% 1% 6% 8% 3%
Whole tumor section 6% 8% 5% 9% 17% 20%
*For small square and small circle, the diagonal diameter of the delineated area is smaller than 5 mm.
Dufraing et al
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whole tumor sections. Overall, no relation of neoplastic cell
content or delineation methods on making technical errors
was observed, but signiﬁcant correlation was obtained
between technical errors and the two extreme ways of
annotating (small circle/small square and whole tumor
section) for 3 years (2013, 2014 to 2015, 2017).
Pitfalls in the Interpretation of Neoplastic Cell Content
The third part of the study covered the interpretation of the
neoplastic cell content. In 2017, 93 of 102 laboratories
(91%) where the neoplastic cell content was estimated in
routine included the neoplastic cell content in their test
report, but only 49 (53%) took it into account for result
interpretation. Of the laboratories that used a noneNGS-
based commercial kit (n Z 51), 75% included the
percentage in the report, and 41% took it into account for
interpretation. For the NGS users (nZ 28), these rates were
82% and 57%, respectively, and for the users of a
noneNGS-based LDT (n Z 23), they were 96% and 57%,
respectively.
During the ESP Colon EQA schemes of 2016 and 2017,
a sample without neoplastic cells was distributed. Of a
total of 123 and 105 participants in 2016 and 2017,
respectively, 10 laboratories in 2016 and 21 in 2017 did
not take the absence of neoplastic cells into account and
genotyped the sample wrongly as wild type. Others (8 in
2016; 12 in 2017) mentioned the zero neoplastic cells in
their report but interpreted this wrongly, for example by
recommending therapy after analysis (6 in 2016; 11 in
2017) or even without analysis (1 in 2017), or by stating
that the sample was suitable for analysis (2 in 2016).
There were also laboratories that incorrectly claimed that
the sample contained neoplastic cells (11 in 2016 and 2 in
2017). Of those 13 laboratories, 7 laboratories reported
that the sample was suitable for analysis and recom-
mended therapy, 5 laboratories added a note that the result
should be interpreted with care due to the low neoplastic
cell content, and 1 laboratory did not submit written
reports.
Six out of seven laboratories that participated both in
2016 and 2017 and genotyped the sample wrongly as a wild
type in 2016 did not make the same mistake in 2017. Five of
six laboratories no longer interpreted zero neoplastic cells
incorrectly in 2017, and no laboratory twice found
neoplastic cells in a sample without them.
Discussion
Neoplastic cell content determination before biomarker
testing is crucial to obtain accurate test results. When the
true neoplastic cell content is around the threshold of the test
method, the result might become dubious because signals
from nontumor DNA dilute signals from tumor DNA.
Overestimations might thus lead to false-negative results
and might keep the patient from receiving the correct ther-
apy. Underestimations, on the other hand, are considered as
less severe, although they might cause retesting and require
an unnecessary search for new samples. Newer testing
techniques, such as NGS, might work with a lower number
of neoplastic cells. Although a reliable estimation might
become redundant in the high range of neoplastic cell
content for this technique, it becomes more critical in the
lower ranges. Furthermore, it is still needed to correctly
interpret the ratio of mutated versus nonmutated alleles. In
this study, current practices used for the determination of
Figure 3 Variation between neoplastic cell content estimations.
*Consensus values were only determined from 2013.
Table 3 Under- and Overestimations Compared with the Sample Mean for All Different Samples per Year
ESP colon EQA scheme year
Number of samples with underestimations Number of samples with overestimations
20% 30% 40% 20% 30% 40%
2011 (N Z 954) 102 (11%) 36 (4%) 4 (1%) 91 (10%) 22 (2%) 3 (0%)
2012 (N Z 762) 116 (15%) 42 (6%) 12 (2%) 103 (14%) 28 (4%) 7 (1%)
2013 (N Z 949) 138 (15%) 49 (5%) 15 (2%) 125 (13%) 38 (4%) 9 (1%)
2014e2015 (N Z 1124) 152 (14%) 59 (5%) 19 (2%) 168 (15%) 50 (4%) 9 (1%)
2016 (N Z 1115) 172 (15%) 71 (6%) 18 (2%) 147 (13%) 47 (4%) 15 (1%)
2017 (N Z 872) 146 (17%) 76 (9%) 23 (3%) 144 (16%) 33 (4%) 11 (1%)
EQA, external quality assessment; ESP, European Society of Pathology.
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neoplastic cell content were analyzed, variances in the
estimations and in the way areas for micro- or macro-
dissection were indicated were evaluated, and in addition,
problems with interpretation of samples without neoplastic
cells were identiﬁed.
Variability in Estimation Processes of Neoplastic Cell
Content Exists
In a small number of laboratories, nonmedical technicians
or medical biologists are determining the neoplastic cell
content with or without pathologist supervision (Figure 2A).
In the future, an increase in this phenomenon is expected to
make the testing process more time- and cost-efﬁcient, and
to anticipate a shortage of pathologists.18e21 Training will
be crucial to prevent that technicians or molecular biologists
become only experts in recognizing patterns without using
clinical and morphological information.19 Also, during
molecular tumor boards, morphological information from
the tumor might be necessary. A large group of pathologists
have not speciﬁed whether they estimated the neoplastic cell
content in a tumor-rich area or in the whole tumor section.
This problem was also elaborated by a French study by
Lhermitte et al11 that states that the lack of a good deﬁnition
for neoplastic cell content causes variability.
Although exact counting of cells (manually or machine-
assisted) might give the most accurate result, this was only
done in three laboratories. The study by Lhermitte et al11
also identiﬁed lymphocytic inﬁltration and extracellular
mucin as factors that impact the estimation. Our study
conﬁrmed these factors and identiﬁed several others such as
the spreading of neoplastic cells, desmoplastic stroma, and
necrosis.
The materials and methods sections of studies often state
that dissection was performed to enrich for tumor content.15,22
In this study, 7% of the laboratories never performed any form
of dissection. Because testing strategies designed for whole
tumor sections are not available yet, this could be poor practice.
For noneNGS-based commercial kits, tissuewasmostly taken
from the block, whereas for noneNGS-based LDTs and NGS,
tissue slides were taken. The reasons for this difference are
unclear, and no statistical differences in neoplastic cell content
estimations and delineation methods were observed. Taking
tissue from an unstained slide might be preferred because it
avoids permanent damage to the tumor block. Although
multiple options exist for taking tissue directly from the tissue
block (eg, punching cylinders out the block or cutting by
knife), this was not further addressed in our study.
Several Factors Inﬂuence Variation in Neoplastic Cell
Content and Delineation of the Tumor Zone
In addition to analyzing current practices, this study aimed
to quantify the variation between different estimations
(Figure 3). Several studies have done this before, however,
not on a large-scale or longitudinally.11e13 In this study, the
average difference between the highest and lowest estima-
tion lies between 52% and 78% between 2011 and 2017
(N Z 5776), which matches the 64% of the AFAQAP
survey [nZ 39 (2012), nZ 44 (2013), and nZ 45 (2014)]
and 68% of the Gen&Tiss survey [n Z 45 (2012), n Z 49
(2013), and nZ 47 (2014)] of Lhermitte et al11 and the 6,3
categories (of 10% increments) from Smits et al12 (n Z 9).
Figure 4 Number of overestimations in sam-
ples with neoplastic cell content around the
diagnostic threshold. From 2013 to 2017, 16
samples with a neoplastic cell content of 30%
were distributed. This ﬁgure shows the number of
overestimations of more than 20% as compared
with the consensus value for those samples. F8,
F10, and so forth refer to sample numbers and
scheme organizers of the given scheme years.
Dufraing et al
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Table 4 Factors Inﬂuencing Neoplastic Cell Content Estimations and Tumor Zone Delineations
Factor Neoplastic cell content estimation Delineation method
Slide rank No significant relationship NA
Delineation method 2011 No significant relationship NA
2012 Precise > gross methods****
Precise > whole tumor section***
2013 Precise > gross methods**
2014e2015 Small circle > gross square**
Small circle > whole tumor section*
2016 Gross methods > whole tumor section****
Precise methods > whole tumor section****
2017 Small circle > gross square*
Small circle > gross tumor shape****
Accreditation status No significant relationship
Except 2017: accredited > nonaccredited****
2011 Nonaccredited & gross square***
Nonaccredited & gross tumor shape***
2012 Nonaccredited & gross methods*
2013 Nonaccredited & whole tumor section*
2014e2015 Nonaccredited & gross methods****
2016 No significant relationship
2017 No significant relationship
Location Figure 5 and Supplemental Table S1
Detection method 2011 Noncommercial > commercial kit**** Commercial kit & whole tumor section*
2012 Noncommercial > commercial kit** Commercial kit & precise methods****
Noncommercial method & whole tumor section****
2013 No significant relationship Commercial kit& gross methods****
Noncommercial method & precise methods****
NGS & gross methods****
2014e2015 No significant relationship Commercial kit & gross methods***
Noncommercial method & precise methods***
NGS & whole tumor section***
2016 Noncommercial > commercial kit****
Noncommercial method > NGS****
No significant relationship
2017 Commercial kit > NGS**
Noncommercial method > NGS*
No significant relationship
Method sensitivity 2011 NA NA
2012 NA NA
2013 Positive correlation**** No significant relationship
2014e2015 No significant relationship Precise methods < gross methods****
Precise methods < whole tumor section****
2016 Positive correlation**** Small circle < gross methods****
2017 Positive correlation** No significant relationship
GE 2011 GE > no GE* No significant relationship
2012 GE > no GE* No significant relationship
2013 No significant relationship GE & gross methods*
GE & whole tumor section*
2014e2015 No GE > GE** GE & whole tumor section***
2016 No significant relationship No significant relationship
2017 GE > no GE* No significant relationship
TE No significant relationship 2011 No significant relationship
2012 No significant relationship
2013 TE & whole tumor section***
2014e2015 TE & small circle**
2016 No significant relationship
2017 TE & small square****
& indicates a correlation exists between both elements (eg, nonaccredited & gross squaremeans that not being accredited is correlatedwith the use of gross squares
as a delineationmethod). For positive correlation, the higher the one, the higher the other. If no distinctionwasmade between different scheme years, the calculated
correlations apply for all years.< indicates smaller sensitivity (eg, precise methods< gross methods means that laboratories that use precise delineation methods
have used mutation detection methods with a lower sensitivity than laboratories that used gross delineation methods).> indicates one factor has higher estimation
than the other (eg, GE > no GE means that laboratories that made a genotyping error have higher estimations than laboratories that made no genotyping error).
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
GE, genotyping error; NA, not applicable; NGS, next-generation sequencing; TE, technical error.
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This study now conﬁrms on a larger and country-wide
scale the ﬁndings of Lhermitte et al11 and Smits et al12 who
also demonstrated that more underestimations than over-
estimations are made. Nevertheless, overestimations are
especially dangerous around the diagnostic threshold of a
test method.10 The percentage of overestimations for sam-
ples containing a low neoplastic cell content (30%,
according to the consensus value) was alarmingly high for
several of those samples (eg, 92% of 13 for a sample from
2014), stressing the need for standardization (Figure 4).
Several factors were signiﬁcantly correlated with
neoplastic cell content estimations and the way the tumor-rich
zone used for dissection is delineated (Table 3). Pathologists
that use precise delineation methods have higher estimations
than those using gross methods. This is logical because by
precisely indicating the tumor, non-neoplastic cells that
contaminate the sample are excluded. Methods for mutation
detection can also impact neoplastic cell content estimations
and tumor delineations because they have different work-
ﬂows and require different minimal amounts of neoplastic
cells for a reliable result.5 Traditional noneNGS-based LDTs
require a higher percentage of minimal neoplastic cells than
non-NGS commercial kits and NGS. This clariﬁes the cor-
relation between the use of noneNGS-based LDTs and a
more precise delineation method, on the one hand, and a
higher neoplastic cell estimation, on the other hand.
Pathologists thus seem to be aware of the fact that the
zone for dissection should be as pure as possible for
methods with lower sensitivity, such as noneNGS-based
LDTs. Variation was also observed between different parts
of Europe. At the moment, reasons for these differences are
unclear and could be further studied.
It was also studiedwhether estimations and delineations were
correlated with the number of genotyping errors and technical
failures (Table 3). Overall, laboratories that made a genotyping
error reported higher neoplastic cell contents and were more
likely to use gross estimation methods or whole tumor sections.
The combination of overestimating the neoplastic cell content
and using a gross estimation method could thus indeed be
dangerous for obtaining false-negative results, as was already
hypothesized by several studies.11e13 In this study, it was not
taken into account whether laboratories made only one or more
than one genotyping error, because a laboratory that made a
genotyping error during an EQA scheme is probably also at risk
for making errors during routine analysis. For technical failures,
two tendencies were observed: using whole tumor sections on
the one hand and using small circles on the other hand. When
whole tumor sections are used, the minimal required percentage
of neoplastic cells is probably not met, and tissue heterogeneity
might be higher than in dissected slides.23 By contrast, using
small samples might lead to technical failures because many
methods also require a minimal absolute number of neoplastic
cells.
Pitfalls in the Interpretation of Neoplastic Cell Content
Several guidelines and checklists (eg, cancer protocols and
checklists from the College of American Pathologists,
available at http://www.cap.org/web/home/protocols-and-
guidelines/cancer-reporting-tools/cancer-protocol-templates,
last accessed December 15, 2017) state that the neoplastic cell
content should be included in the test report.24,25 Most labo-
ratories in this study are doing this; however, this information is
not always taken into account when interpreting the test result.
These ﬁndings were also previously conﬁrmed by a study by
Tembuyser et al17 in which a sample with a borderline
neoplastic cell content led to a higher rate of false-negative
results. The fact that many laboratories do not use the
neoplastic cell content when interpreting test results could
affect patient outcome. Although clinicians who read the re-
ports usually have basic knowledge about testing techniques, it
is uncertain whether they know what to do with this informa-
tion without a clear interpretation. And even when the
neoplastic cell content is interpreted, this is not always done
correctly as was demonstrated by the samples without any
neoplastic cells. These results stress the need for training pa-
thologists and residents in the ﬁeld of molecular pathology.
Molecular analysis in a sample without neoplastic cells is a
waste of time and money, and incorrectly reporting wild-type
results could harm the patient. It is very concerning that in
Figure 5 Variation between different parts of Europe. Summary of the
relationship between places in Europe and the estimation of the neoplastic
cell content as well as between places and tumor zone delineation from
2011 until 2017 (Table 3). EQA, external quality assessment; ESP, European
Society of Pathology; NC%, percentage neoplastic cells.
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2016, 10%of the pathologists identiﬁed non-neoplastic cells as
neoplastic cells. This might indicate a certain unawareness of
the importance of the determination of the neoplastic cell
content. These data also show that the majority of laboratories
thatmade an interpretation error in 2016 did notmake the same
mistake in 2017. A learning process is thus already triggered
and stresses the need for continued education and participation
in EQA schemes.
Next Steps
In this study, digital tools to estimate the neoplastic cell
content were not used by any of the participating laboratories.
At the moment, a limited number of systems are commer-
cially available for in vitro diagnostic use in Europe.26,27 If
these digital tools are thoroughly validated and trained to
recognize neoplastic cells, they might be a solution for
interobserver variation. Therefore, further comparisons
between visual and digital estimations should be made. On
the other hand, laboratories will not immediately make the
switch to digital estimations. It is thus important that sufﬁ-
cient attention is paid to the determination of the neoplastic
cell content and additional training is needed, for the delin-
eation of the tumor area and the neoplastic cell content esti-
mation, but also for reporting and interpreting. Because
molecular testing is becoming organized in amore centralized
way,28 selection of the most suitable block for molecular
analysis and a clear report will become even more important.
Also in case of centralization, pathologists have a duty to
check the sample selected for molecular analysis on H&E for
neoplastic cell content, because they cannot be certain who
selected the sample and if there was a review before shipment
to the central laboratory. The authors have already initiated a
project to develop a best-practice guideline. Ten experts from
10 different countries were invited to obtain consensus on the
following topics; the individual who should perform the
morphological evaluation of the sample and who should
determine the neoplastic cell content, selection of the most
viable tumor area, assessment of the homogeneity of the
sample, practices for macrodissection, necessary control
steps, and requirements for reporting.
Conclusions
An accurate estimation of the neoplastic cell content is
essential for reliable biomarker testing. Variation in the
different practices for the indication of the zone for micro-
or macrodissection and the estimation of the neoplastic cell
content in that zone exists. Moreover, variation in tumor
zone delineations and cellularity estimations between
different pathologists was quantiﬁed. In addition, a high
number of overestimations in samples containing a
neoplastic cell content around the threshold of the test
methods was observed. The post-analytical use of
neoplastic cell content information should also be
improved, since reporting false negative results could
affect patients. Standardization of practices is thus neces-
sary for assuring that the minimal percentage of neoplastic
cells that is required for testing methods is met and for
correctly interpreting the results. This process could be
assisted by conceiving and distributing a best practice
guideline.
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